Glioma is a condition which covers a broad category of brain and spinal cord tumors that come from glial cells in brain that support nerve cells.
Glioma Therapeutics Market: Emerging Chemotherapies can be Effective Treatment Options
- Glioma is a condition which covers a broad category of brain and spinal cord tumors that come from glial cells in brain that support nerve cells. Glioma can affect brain function and may be fatal depending on its location and severity of tumor.
- Glial cells are cells in brain which surround and support neurons in the brain including astrocytes, oligodendrocytes, and ependymal cells. Glioma is a common type of tumor originating in the brain which is formed in these glial cells.
Read Report Overview - https://www.transparencymarketresearch.com/glioma-therapeutics-market.html
- Glioma has different types such as astrocytoma, brain stem gliomas, ependymomas, mixed gliomas (oligo-astrocytomas), oligodendrogliomas, and optic pathway gliomas
- Risk factors may range from older age (more common in adults between 45-65 years of age) and radiation exposure to family history of glioma
- Various therapeutic options are available for the treatment of glioma such as radiation therapy, chemotherapy, targeted drug therapy, and surgery. Late stage clinical pipeline drugs can be effective treatment options for glioma in the next few years.
Key Drivers and Restraints of Global Glioma Therapeutics Market
- Expected approval of late-stage pipeline molecules and orphan drug designation to certain molecules for the treatment of glioma are some of the major factors responsible for the growth of the global glioma therapeutics market
- For instance, on December 05, 2019, U.S. FDA and European Medicines Agency granted orphan drug designation to Adastra Pharmaceuticals drug zotiraciclib, a multikinase inhibitor. This products is being evaluated in two phase 1b clinical studies of patients with glioblastoma, the most common glioma histology for the treatment of glioma.
- Growing prevalence of brain cancer and rising awareness regarding various types of brain tumors are some of the major factors fuelling the growth of global glioma therapeutics market
- Moreover, strategic alliances for the development of glioma therapeutics products and increase in exposure of humans to radiation in recent times which leads to higher incidence of brain cancer are some of the major factors responsible for the growth of the global glioma therapeutics market
Request a PDF Brochure - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=76325
Adverse Effects of Chemotherapy Hamper Market:
Regrowth of tumor after treatment & surgery in many cases and adverse effects of chemotherapy are some of the factors hampering the growth of the global glioma therapeutics market
Increase in investment in developing new molecules and unsuccessful trials can also negatively impact the global glioma therapeutics market
Chemotherapy Segment to be Highly Lucrative Segment
- Based on therapy type, global glioma therapeutics market can be segmented into chemotherapy, targeted drug therapy, radiation therapy, and surgery
- Chemotherapy is a highly promising segment of the market which is expected to show significant growth during the forecast period, owing to expected launch and approval of new molecules for glioma treatment and higher investment of companies for pipeline products in this category
- The chemotherapy segment is further sub-segmented into Temozolomide, Bevacizumab, Carmustine, and others
Request for TOC @ https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=76325
Low Grade Gliomas to be Promising Grade Segment
- In terms of grade, the global glioma therapeutics market can be divided into low-grade gliomas, high-grade gliomas, and recurrent high-grade gliomas
- The low-grade gliomas segment is anticipated to be a highly lucrative segment in the near future due to more treatment options availability and early detection of tumor of this grade
Primary Dominated Tumor Type Segment
- Based on tumor type, the global glioma therapeutics market can be bifurcated into primary tumors and secondary tumors
- Primary tumors are further sub-divided into astrocytoma, ependymoma, brain stem gliomas, oligodendrogliomas, mixed gliomas, and others
- Primary tumors dominated the global glioma therapeutics market as they are a more prevalent form of tumors across the world
North America to Dominate Global Glioma Therapeutics Market
- In terms of region, the global glioma therapeutics market can be divided into: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
- North America dominated the global glioma therapeutics market in 2018 due to approval of new products for glioma treatment, higher prevalence of brain tumor cases in the region, growing exposure of population to radiation, and presence of major companies in the region
- For instance, as per the American Society of Clinical Oncology (ASCO) stats, an estimated 23,820 adults in the U.S. are diagnosed with primary cancerous tumors of the brain and spinal cord in 2018. Brain tumors accounted for 85% to 90% of all primary CNS tumors.
- The market in Asia Pacific is expected to be highly attractive during the forecast period due to launch of approved products in the region in later half of forecast period, higher number of geriatric population, increase in patients with cancer, and rise in awareness regarding diseases & treatment
Pre Book Glioma Therapeutics Market Research - https://www.transparencymarketresearch.com/checkout.php?rep_id=76325<ype=S
Key Manufacturers Operating in global Market
Key manufacturers operating in the global market are:
- Hoffmann-La Roche Ltd.
- Merck & Co., Inc.
- Amgen Inc.
- Adastra Pharmaceuticals
- NextSource Biotechnology, LLC
- Novartis AG
- Mylan N.V.
- Pfizer Inc.
- Bristol-Myers Squibb Company
- Arbor Pharmaceuticals, LLC
Browse more Reports by Transparency Market Research:
Lyme Disease Diagnostics Market: The world has witnessed a rising number of Lyme disease cases in recent years, and expected to further grow with increasing worldwide population. People living in wooded areas are more likely to undergo Lyme disease tests. In addition, with the rising cases of tick-borne infectious diseases and increasing incidences of new types of vector-borne diseases, the demand for new diagnostics centers and improved diagnostics is gradually rising favoring the global Lyme disease diagnostics market.
Lyme Disease Treatment Market: Rise in prevalence of Lyme disease, high demand for effective treatment, increase in awareness about tick borne diseases, and business strategies adopted by key players are key factors projected to fuel the growth of the global Lyme disease treatment market during the forecast period.
About Us
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.
Contact
Mr. Rohit Bhisey
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: https://www.transparencymarketresearch.com/